0
0
The NVX-CoV2373 vaccine is said to have 90.4 percent efficacy. What makes it special: It is neither a vector nor an mRNA vaccine.
A vaccine candidate from U.S. manufacturer Novavax offers a high level of protection against Covid-19, according to the company. The efficacy of the NVX-CoV2373 vaccine, which must be injected twice, is 90.4 percent, according to the results of a Phase 3 study. That means subjects in the vaccinated group had about 90 percent less disease than participants in the control group. Protection against moderate and severe courses of the disease was even 100 percent.
In general, the vaccination was well tolerated, it was added. Participants reported temporary pain at the injection site as well as fatigue, headache and muscle pain. The study involved 29,960 people aged 18 and older in the United States and Mexico.
NVX-CoV2373, unlike previously approved vaccines, is neither an mRNA vaccine – like the preparations from Biontech/Pfizer and Moderna – nor a vector vaccine like Astrazeneca’s: the vaccine contains tiny particles composed of a laboratory-produced version of the spike protein from Sars-CoV-2.
Development of the vaccine had been heavily funded by the U.S. government. Novavax said it plans to file for approval in the third quarter of the year. In the EU, an accelerated review process has been underway since February. This so-called rolling review process will continue until sufficient data is available for a formal application for approval.
Around 150 million doses of the vaccine could be produced by the end of 2021, Novavax said. However, since the U.S. already has sufficient vaccine available, Novavax’s preparation is expected to be prioritized for use elsewhere.
— source: heute.at/picture: pharmaceutical-technology.com
This post has already been read 561 times!
